Risk of heart disease following breast cancer: results from a population-based cohort study

BACKGROUND: There is a rising concern about treatment-associated cardiotoxicities in breast cancer patients.OBJECTIVES?This study aimed to determine the time- and treatment-specific incidence of arrhythmia, heart failure and ischemic heart disease in women diagnosed with breast cancer. METHODS: A register-based matched cohort study was conducted including 8338 breast cancerpatients diagnosed from 2001-2008 in the Stockholm-Gotland region and followed-up until 2017. Overall and time dependent risks of arrhythmia, ischemic heart disease and heart failure in breast cancer patients were assessed using flexible parametric models as compared to matched controls from general population. Treatment-specific effects were estimated in breast cancer patients using Cox model.RESULTS: During a median follow-up of 10.8 years, the hazard ratios for arrhythmia, heart failure and ischemic heart disease, were 1.27 (95% CI = 1.18-1.37), 1.38 (95% CI = 1.23-1.55), and 0.93 (95% CI = 0.84-1.03), respectively. Time-dependent analyses revealed long-term increased risks of arrhythmia, and heart failure in breast cancer patients compared to matched controls. The risk of ischemic heart disease was only elevated in the first year after cancer diagnosis. Trastuzumab and anthracyclines were associated with increased risk of heart failure. Aromatase inhibitors, but not tamoxifen, were associated with risk of ischemic heart disease. No increased risk of heart disease was identified following loco-regional radiotherapy.CONCLUSIONS: Administration of systemic adjuvant therapies appear to be associated with increased risks of heart disease. The risk estimates observed in this study may serve as reference to aid adjuvant therapy decision-making and patient counseling in oncology practices.

Although the benefits of radiotherapy far outweigh the risk of heart diseases, some studies 73 have found increased incidence of and mortality due to heart disease in women subjected to remains increased for standard low-dose group as compared to non-users (Chung et al., 2020). 79 While trastuzumab has been shown to reduce the risk of breast cancer mortality at 11 years of is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.16.21263682 doi: medRxiv preprint failure, compared to tamoxifen (Khosrow-Khavar, Filion, Bouganim, Suissa, & Azoulay, 84 2020). 85 Risk assessment of immediate and later occurring heart disease events following breast 86 cancer is important for the planning of cardiac surveillance programs and possible prophylactic 87 pharmacotherapy. Here, we report the risks of heart diseases in in a cohort representative of the 88 general breast cancer population with long-term follow-up. We specifically aimed to assess 89 risks of heart diseases by time since diagnosis, and according to adjuvant treatments. the breast cancer cohort can be found elsewhere (Holm et al., 2016).

111
The study was approved by the Regional Ethical Review Board in Stockholm.

121
Breast cancer treatment specifics 122 We extracted the treatment data from the Stockholm-Gotland Breast Cancer Register.   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint characteristics were also retrieved from this register, including tumor size (T), regional lymph  Next, we studied the association of adjuvant breast cancer therapy with heart disease risk 156 in breast cancer patients using Cox proportional hazards models. We adjusted these analyses cancer stage, type of surgery, CCI score, history of heart disease, hypertension, chronic 159 pulmonary disease and tobacco abuse. All treatment specific models were mutually adjusted  follow-up periods, within 10 years after breast cancer diagnosis and beyond, respectively.

168
All statistical analyses were performed using STATA version 15.1.

170
Descriptive characteristics of the study population are described in Over a median follow-up of 10.8 years (interquartile range = 6.5 years) arrhythmias were 177 the most frequently reported heart disease (n = 677), followed by ischemic heart disease (n = 178 384) and heart failure (n = 306). The cumulative incidence of arrhythmias, ischemic heart 179 disease and heart failure in the cohort was 12.10%, 6.55% and 5.59% after 15 years of follow-  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

187
. CC-BY 4.0 International license It is made available under a perpetuity.

191
Hazard ratios of for arrhythmias, ischemic heart disease and heart failure were not notably 192 different in women with or without a previous diagnosis of these respective heart diseases.

193
Analyses by time since diagnosis revealed a short-term increase in risks of arrhythmia and 194 heart failure ( Table 2). An elevated risk of ischemic heart disease was observed in the first year 195 after diagnosis (HR = 1.48; 95% CI = 1.14-1.91), followed by a decline with increasing follow-    is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021.   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021. ;  In a population-based setting, we demonstrated that the incidence of heart disease in breast 246 cancer patients was significantly higher than the incidence observed in matched reference 247 individuals from the general population. The risks of arrhythmia and heart failure were 248 increased even beyond 15 years after diagnosis. Receipt of trastuzumab, as well as 249 administration of anthracycline +/-taxane-based regimens were independently associated with 250 an increased risk of heart failure, while aromatase inhibitor therapy was associated with an 251 increased risk of ischemic heart disease. 252 We found an increased risk of arrhythmia and heart failure in breast cancer patients as 253 compared with the matched reference individuals from the general population, which is similar 254 to the risk of heart failure reported by a previous Dutch study (Hooning et al., 2007), indicating 255 the generalizability of our findings within European countries. In the present study, we further 256 found similar magnitude HRs estimates in patients with and without a previous diagnosis of 257 heart disease, suggesting no effect modification by disease history.

258
Analysis by time since diagnosis from the current study revealed long-term increased risks 259 of arrhythmia and heart failure following breast cancer. The long-term increased risk of heart 260 failure potentially reflects the profound cardiotoxic effect of anthracyclines, as we found 261 increased risk of heart failure in patients treated with anthracyclines beyond 10 years after 262 cancer diagnosis. As the long-term risk was observed for heart failure but not ischemic heart 263 disease, we hypothesized that the cardiotoxic effect of chemotherapy was mainly on the 264 myocardium but not the cardiac vessels. The finding that risk of ischemic heart disease in breast 265 cancer patients may be shortly elevated after diagnosis, but diminish over time is not  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021.   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint  Kirby, 2015). Therefore, in our study, we compared risk of 299 ischemic heart disease in patients treated with radiotherapy for left-sided to those treated for 300 right-sided breast cancer. We found slightly increased non-significant risk of ischemic heart 301 disease, this risk appeared (as expected) more pronounced in the follow-up period after 10 302 years. Overall, our results indicate only small risk of heart disease due to radiotherapy in women 303 treated in Sweden after year 2000.

304
A major strength of our study is that we were able to investigate risks of heart disease by  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021.    is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted September 21, 2021. ; https://doi.org/10.1101/2021.09.16.21263682 doi: medRxiv preprint study. All authors acquired, analyzed, or interpreted the data. HY and NBP drafted the  is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint   is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint